Citarinostat

Phase 1Small molecule

MMassachusetts General Hospital

Citarinostat is one of 18 small molecule programs targeting Lenalidomide. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LenalidomideActive, not recruiting

LenalidomidePhase 1

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Lenalidomide

#DrugCompanyPhaseTrials

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

54 2

Rituxan

Roche

Phase 3

15 3

Decadron

AAspen Global Incorporated

Phase 3

5 4

Gazyva

Roche

Phase 2

2 5

Oncovin

Eli Lilly

Phase 2

2 6

Adriamycin

Pfizer

Phase 2

2 7

Trexall

Jazz Pharmaceuticals

Phase 2

2 8

Belamaf

GSK

Phase 2

1 9

Calquence

AstraZeneca

Phase 2

1 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lenalidomide1 trial

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT02886065·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Citarinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Citarinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Citarinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMassachusetts General Hospital

Citarinostat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lenalidomide1 trial

References

Drug Info

Quick Facts

Related News